Home » Topics » BioWorld Science

BioWorld Science
RSS

Galectin Therapeutics submits phase III protocol for NASH-RX trial to the FDA

Aug. 6, 2019

Complete wound healing reported in first patient treated in phase II study of RGN-137

Aug. 6, 2019

FDA clears IND application for phase IIb ASTONISH study of nangibotide

Aug. 6, 2019

HIV: exosomes potentiate inflammation in bystander cells

Aug. 6, 2019

Zydus completes phase III trials of saroglitazar in type 2 diabetes mellitus

Aug. 6, 2019

Mitsubishi Tanabe Pharma announces initiation of development of gene therapy for hemophilia B

Aug. 6, 2019

IPH-4102 shows promising activity in cutaneous T-cell lymphoma in first-in-human study

Aug. 6, 2019

Basilea announces positive results from phase III TARGET study of ceftobiprole in ABSSSI

Aug. 6, 2019

Sanofi reports updates for Dupixent as treatment in adolescents and children with atopic dermatitis

Aug. 6, 2019

Pivotal IMPALA study of lefitolimod in colorectal cancer misses primary endpoint

Aug. 6, 2019

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...